Mrs Olukemi Abike Alegi, MD | |
1270 Prince Avenue, Suite 102, Athens, GA 30606 | |
(706) 475-7055 | |
Not Available |
Full Name | Mrs Olukemi Abike Alegi |
---|---|
Gender | Female |
Speciality | Student In An Organized Health Care Education/training Program |
Location | 1270 Prince Avenue, Suite 102, Athens, Georgia |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1639866403 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
2085R0001X | Radiology - Radiation Oncology | R-13021 (Iowa) | Secondary |
390200000X | Student In An Organized Health Care Education/training Program | (* (Not Available)) | Primary |
Mailing Address | Practice Location Address |
---|---|
Mrs Olukemi Abike Alegi, MD 200 Hawkins Dr, Iowa City, IA 52242-1009 Ph: (319) 384-6135 | Mrs Olukemi Abike Alegi, MD 1270 Prince Avenue, Suite 102, Athens, GA 30606 Ph: (706) 475-7055 |
News Archive
More than half of people with diabetes who take insulin injections to control their diabetes say they have intentionally skipped an injection, with one-fifth of them reporting that they do so "sometimes" or "often," according to a study being published this month in Diabetes Care.
Actinium Pharmaceuticals, Inc. ("Actinium" or "the Company"), a biopharmaceutical company developing innovative targeted payload immunotherapeutics for the treatment of advanced cancers, today announced that Actinium's Clinical Advisory Board Chairman Joseph Jurcic, MD will participate in an upcoming panel discussion highlighting the role of Actinium's alpha-particle radiopharmaceuticals in the treatment of leukemia patients.
A team of researchers have found that the American workplace is a significant contributor to the obesity epidemic. In the review of shifts in the labor force since 1960 it was suggested that a sizable portion of the national weight gain can be explained by declining physical activity during the workday.
Gilead Sciences, Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved Stribild (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), a complete once-daily single tablet regimen for HIV-1 infection for treatment-naïve adults.
› Verified 2 days ago